Astria Therapeutics
ATXS
ATXS was delisted on the 22nd of January, 2026.
28 hedge funds and large institutions have $18.4M invested in Astria Therapeutics in 2018 Q3 according to their latest regulatory filings, with 8 funds opening new positions, 4 increasing their positions, 7 reducing their positions, and 10 closing their positions.
1.14% less ownership
Funds ownership: 1.68% → 0.54% (-1.1%)
7% less funds holding
Funds holding: 30 → 28 (-2)
20% less first-time investments, than exits
New positions opened: 8 | Existing positions closed: 10
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
34% less capital invested
Capital invested by funds: $28.1M → $18.4M (-$9.66M)
43% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 7
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OC
Oppenheimer & Co
New York
|
+$232K |
| 2 |
Northern Trust
Chicago,
Illinois
|
+$109K |
| 3 |
BlackRock
New York
|
+$74.4K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$53.6K |
| 5 |
Russell Investments Group
London,
United Kingdom
|
+$17.5K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$1.92M |
| 2 |
CH
CVI Holdings
Wilmington,
Delaware
|
-$1.46M |
| 3 |
Alyeska Investment Group
Chicago,
Illinois
|
-$840K |
| 4 |
Millennium Management
New York
|
-$335K |
| 5 |
Renaissance Technologies
New York
|
-$285K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
26
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$45 | +1 | +7% |
|
|
FIA
27
FNY Investment Advisers
New York
| $1K | +$1.48K | +33 | New |
|
|
MFW
28
Mosaic Family Wealth
St. Louis,
Missouri
| $1K | +$1.62K | +36 | New |
|
|
AC
29
Armistice Capital
New York
| – | -$1.92M | -33,333 | Closed |
|
|
30
Alyeska Investment Group
Chicago,
Illinois
| – | -$840K | -18,692 | Closed |
|
|
HI
31
HBK Investments
Dallas,
Texas
| – | -$192K | -3,333 | Closed |
|
32
Dimensional Fund Advisors
Austin,
Texas
| – | -$147K | -2,550 | Closed |
|
33
Jacobs Levy Equity Management
Florham Park,
New Jersey
| – | -$95K | -1,655 | Closed |
|
|
SIM
34
Spark Investment Management
New York
| – | -$69K | -1,213 | Closed |
|
35
Citadel Advisors
Miami,
Florida
| – | -$38K | -664 | Closed |
|
|
HF
36
HRT Financial
New York
| – | -$23K | -400 | Closed |
|
37
Jane Street
New York
| – | -$22K | -387 | Closed |
|
|
VF
38
Virtu Financial
New York
| – | -$19K | -323 | Closed |
|
ATXS Hedge Fund Activity: Q3 2018 in Review
28 of the 4,375 institutional investors tracked by Wall St. Rank reported a position in Astria Therapeutics (ATXS) for Q3 2018, worth a combined $18.4M — down 34% from $28.1M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of ATXS and 8 opened new positions — a net loss of 2 holders — while 7 trimmed existing stakes and 4 added.
The largest buyer was Oppenheimer & Co, adding an estimated $232K. The largest seller was Armistice Capital, exiting entirely with an estimated $1.92M sold.
- 28 institutional investors held Astria Therapeutics (ATXS) as of Q3 2018, down from 30 in Q2 2018.
- Funds reported $18.4M of Astria Therapeutics stock for Q3 2018, down 34% quarter-over-quarter.
- 8 funds opened new Astria Therapeutics positions in Q3 2018 and 10 closed out, a net change of -2 holders.
- The largest Astria Therapeutics buyer in Q3 2018 was Oppenheimer & Co, an estimated $232K added.
- The largest Astria Therapeutics seller in Q3 2018 was Armistice Capital, an estimated $1.92M sold.
Based on aggregated 13F filings for Q3 2018.